Chaparro Mérida Nataniel Aldo, Moreno Samper Dayany, Lacato Alex Omar Franco
PROSALUD, Cochabamba, Bolivia.
Hospital Clínico Quirúrgico Docente «Salvador Allende», Cuba.
Rev Peru Med Exp Salud Publica. 2021 Oct-Dec;38(4):634-642. doi: 10.17843/rpmesp.2021.384.9308. Epub 2022 Apr 1.
The development and production of safe and effective vaccines against coronavirus disease 2019 (COVID-19) provides hope for controlling the current pandemic. Adverse events following immunization are unwanted responses or unintended events that must be carefully monitored, as all vaccines, including those developed against SARS-CoV-2, are required to meet safety criteria for administration in humans. Information was collected from the PubMed/Medline database during the months of August 2020 to November 2021. Most adverse events reported in clinical trials were mild or moderate; however, thrombotic events associated with some viral vector-based vaccines against COVID-19 were identified in follow-up studies, although completion of the various ongoing studies and post-marketing surveillance is required to determine all potential adverse events, as well as those of special interest.
研发和生产针对2019冠状病毒病(COVID-19)的安全有效疫苗为控制当前的大流行带来了希望。免疫接种后的不良事件是需要仔细监测的不良反应或意外事件,因为所有疫苗,包括针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)研发的疫苗,都必须符合用于人体接种的安全标准。在2020年8月至2021年11月期间从PubMed/Medline数据库收集了信息。临床试验中报告的大多数不良事件为轻度或中度;然而,在后续研究中发现了与一些基于病毒载体的COVID-19疫苗相关的血栓形成事件,不过需要完成各项正在进行的研究和上市后监测,以确定所有潜在的不良事件以及那些特别受关注的不良事件。